Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi & Co. Ltd.

www.shionogi.co.jp

Latest From Shionogi & Co. Ltd.

Pipeline Watch: Patisiran, Etrolizumab, ALKS8700 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Interfering Virus: A New Treatment Strategy For Flu

The UK's VirionHealth has taken £13m on board in a Series A to develop a novel approach to the treatment of influenza virus infections.

Financing Infectious Diseases

Pipeline Watch: Topline Phase III Results For Caplacizumab, Relugolix, Iclaprim

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Pipeline Watch: Phase III Progress With Esaxerenone, Lusutrombopag

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Company Type
  • Top Japanese Pharma
  • Parent & Subsidiaries
  • Shionogi & Co. Ltd.
  • Senior Management
  • Isao Teshirogi, PhD, Pres. & CEO
  • Contact Info
  • Shionogi & Co. Ltd.
    Phone: (81) 6 6202 2161
    1-8, Doshomachi 3-chome
    Chuo-ku
    Osaka, 541 0045
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register